TScan Therapeutics, Inc. (TCRX)
Nasdaq: TCRX · Biological Products, (No Diagnostic Substances) · Waltham, MA · filing with the SEC since 2019
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Report filed | Mar 4, 2026 | Mar 5, 2025 | Mar 6, 2024 | Mar 8, 2023 | Mar 9, 2022 | · |
| Revenue | 10,325 | 2,816 | 21,049 | 13,535 | 10,141 | 1,085 |
| Research and development | 114,150 | 107,350 | 88,153 | 59,819 | 44,954 | 20,577 |
| General and administrative | 31,988 | 30,287 | 26,354 | 20,352 | 13,828 | 6,741 |
| Total operating expenses | 146,138 | 137,637 | 114,507 | 80,171 | 58,782 | 27,318 |
| Operating income | -135,813 | -134,821 | -93,458 | -66,636 | -48,641 | -26,233 |
| Interest expense | 2,769 | 3,653 | 3,759 | 1,176 | · | · |
| Other income (expense), net | 6,047 | 7,322 | 4,240 | 415 | 16 | · |
| Income tax expense | 0 | · | · | · | · | · |
| Net income including non-controlling interests | -129,766 | -127,499 | -89,218 | -66,221 | -48,625 | -26,127 |
| Net income | -129,766 | -127,499 | -89,218 | -66,221 | -48,625 | -26,127 |
| Earnings per share, basic | -1.00 | -1.14 | -1.36 | -2.75 | -4.17 | · |
| Earnings per share, diluted | -1.00 | -1.14 | -1.36 | -2.75 | -4.17 | · |
| Earnings per share, basic and diluted | · | · | · | · | -4.17 | -28.52 |
| Weighted average shares, basic | 129,777,415 | 111,990,417 | 65,599,858 | 24,048,267 | 11,662,672 | · |
| Weighted average shares, diluted | 129,777,415 | 111,990,417 | 65,599,858 | 24,048,267 | 11,662,672 | · |
| Weighted average shares, basic and diluted | · | · | · | · | 11,662,672 | 916,014 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted